Archive for category Pharma

Up in the air

PME Pharmaceutical Market Europe May 2017

Stranger things have been said by politicians, particularly recently, but I can’t have been the only person surprised by Greg Clark’s turn at this year’s ABPI annual conference.

Asked about the EMA Clark, the UK government’s spokesperson for business, energy and industrial strategy, told the UK pharma gathering he wanted “as many [European] institutions here as possible”, adding: “I would like the EMA to continue to be within the UK.”

Meanwhile, in the real world, the temperature is certainly rising on the issue of where Europe’s regulatory authority will be located, with ‘not in the UK’ seemingly the only certainty at the moment. A decision from the EU’s heads of government is expected in the Autumn, and Copenhagen, Barcelona, Dublin and Lisbon are among those stepping up their public campaigns to host the EMA. Read the rest of this entry »

, , , , , ,

Leave a comment

A marathon, not a sprint

PME Pharmaceutical Market Europe April 2017

The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.

Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.

Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »

, , , , ,

Leave a comment

Employee engagement and nurturing talent in pharma

PME Pharmaceutical Market Europe March 2017

You won’t generally find PME issues following a particular theme each month – there’s simply too much interesting ground to cover in the magazine for that.

Nevertheless, as each issue coalesces there are often common strands across different features and such seemed the case with March’s PME, which contains a nice chunk of ‘careers’ content.  Read the rest of this entry »

, , , , , , , , ,

Leave a comment

Stability and change

PME Pharmaceutical Market Europe pharma magazine March 2017In this month’s issue of PME magazine we balance the changes that are already the theme of 2017 with some much needed stability in the form of a look at family-owned or foundation-run pharmaceutical companies.

Such European businesses include Germany’s Boehringer Ingelheim, Italy’s Chiesi and Denmark’s LEO Pharma, whose president and CEO Gitte Aabo talked to us about playing the long game and how this sees it through times of boom and bust. Read the rest of this entry »

, , ,

Leave a comment

Science to meet art at Science Gallery London

Science Gallery London

At almost 310 metres high The Shard is the tallest building in the capital, towering over its London neighbours in Southwark.

One of those in its shadow is the site for what will become Science Gallery London, an exhibition and performance space that, from 2018, hopes to connect scientific researchers, students, local communities and artists. Read the rest of this entry »

, , , ,

Leave a comment

Ready to start?

PME Pharmaceutical Market Europe January 2017

As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.

This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »

, , , ,

Leave a comment

2016? We’ve been set up

In screenwriting the three-act structure progresses from setup to confrontation to resolution, with the first act used for establishing the main characters.

It’s a device for fiction of course, but much of this year feels like just that. In fact, looking back on the last 12 months, 2016 also feels like a setup for events yet to come. Read the rest of this entry »

, , , ,

Leave a comment

%d bloggers like this: